Our Goal is to Transform Care for Patients with GIST
We are committed to transforming the lives of patients with GIST. At IDRx, we believe that the best treatments for patients target their tumors in multiple ways.
Rather than trying to create a single drug molecule that attempts to address all mutations that may be driving your GIST, we are inspired by the successful drug cocktails in other disease areas such as cystic fibrosis and HIV – approaches that have transformed the lives of people with those diseases.
We are developing a targeted combination of drugs to treat the large majority of GIST tumors driven by mutations in the KIT enzyme. This combination utilizes a primary therapy (IDRX-42) designed to be a potential best in class therapy, potently inhibiting a broad range of primary mutations that drive the progression of most cases of GIST, and a second therapy (IDRX-73) designed to selectively address a key resistance mutation that is challenging for most therapies to address. We aim to intervene earlier in the course of patients' disease to address these mutations. We believe this approach has the potential to offer prolonged, durable, and better tolerated therapeutic responses for people living with GIST.
Currently Enrolling Clinical Trials
IDRx is conducting a Phase 1 first-in-human study of IDRX-42, a small molecule tyrosine kinase inhibitor designed to target key genetic driver and resistance mutations in GIST. The study is currently enrolling adult participants with metastatic and/or unresectable GIST in the U.S. and Europe.